Tags

Type your tag names separated by a space and hit enter

PPARs and nonalcoholic fatty liver disease.
Biochimie. 2017 May; 136:65-74.B

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis. Without intervention it can progress to end-stage liver disease and hepatocellular carcinoma. Given its close association with obesity, the prevalence of NAFLD has increased dramatically worldwide. Currently, there are no FDA-approved medications for the treatment of NAFLD and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients. As such, the search for effective therapeutic agents is an active area of research. Peroxisome proliferator-activated receptors (PPARs) belong to a class of nuclear receptors. Because of their key role in the transcriptional regulation of mediators of glucose and lipid metabolism, PPAR ligands have been investigated as possible therapeutic agents. Here we review the current evidence from preclinical and clinical studies investigating the therapeutic potential of PPAR ligands for the treatment of NAFLD.

Authors+Show Affiliations

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110, USA.Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA. Electronic address: bfinck@wustl.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27916647

Citation

Liss, Kim H H., and Brian N. Finck. "PPARs and Nonalcoholic Fatty Liver Disease." Biochimie, vol. 136, 2017, pp. 65-74.
Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie. 2017;136:65-74.
Liss, K. H., & Finck, B. N. (2017). PPARs and nonalcoholic fatty liver disease. Biochimie, 136, 65-74. https://doi.org/10.1016/j.biochi.2016.11.009
Liss KH, Finck BN. PPARs and Nonalcoholic Fatty Liver Disease. Biochimie. 2017;136:65-74. PubMed PMID: 27916647.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PPARs and nonalcoholic fatty liver disease. AU - Liss,Kim H H, AU - Finck,Brian N, Y1 - 2016/12/02/ PY - 2016/10/24/received PY - 2016/11/23/revised PY - 2016/11/28/accepted PY - 2016/12/6/pubmed PY - 2017/5/26/medline PY - 2016/12/6/entrez KW - Fibrates KW - Liver KW - NAFLD KW - NASH KW - PPAR KW - Thiazolidinediones SP - 65 EP - 74 JF - Biochimie JO - Biochimie VL - 136 N2 - Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis. Without intervention it can progress to end-stage liver disease and hepatocellular carcinoma. Given its close association with obesity, the prevalence of NAFLD has increased dramatically worldwide. Currently, there are no FDA-approved medications for the treatment of NAFLD and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients. As such, the search for effective therapeutic agents is an active area of research. Peroxisome proliferator-activated receptors (PPARs) belong to a class of nuclear receptors. Because of their key role in the transcriptional regulation of mediators of glucose and lipid metabolism, PPAR ligands have been investigated as possible therapeutic agents. Here we review the current evidence from preclinical and clinical studies investigating the therapeutic potential of PPAR ligands for the treatment of NAFLD. SN - 1638-6183 UR - https://www.unboundmedicine.com/medline/citation/27916647/PPARs_and_nonalcoholic_fatty_liver_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0300-9084(16)30292-9 DB - PRIME DP - Unbound Medicine ER -